BACKGROUND: Streptococcus pyogenes causes more than 500 000 deaths per year globally, which occur disproportionately in low-income and middle-income countries. The roles of S pyogenes skin and pharyngeal carriage in transmission are unclear. We aimed to investigate the clinical epidemiology and household transmission dynamics of both S pyogenes asymptomatic carriage and infection in a high-burden setting.
METHODS: We did a 1-year prospective, longitudinal, household cohort study, recruiting healthy participants from households in Sukuta, The Gambia. Households were eligible if they comprised at least three members, including one child younger than 18 years, and were excluded if more than half of household members declined to participate. Households were identified by random GPS coordinates derived from census data. At monthly visits, pharyngeal and normal skin swabs were collected for S pyogenes culture, and sociodemographic data were recorded by interview. Incident pharyngitis and pyoderma infections were captured. Cultured isolates underwent emm genotyping. The primary outcome measures were incidence of S pyogenes carriage and disease. Additional outcomes were prevalence of S pyogenes skin and pharyngeal carriage, S pyogenes skin and pharyngeal clearance time, S pyogenes emm type, risk factors for carriage and disease events, household secondary attack rate, and emm-linked household transmission events. The study is registered on ClinicalTrials.gov, NCT05117528.
RESULTS: Between July 27, 2021, and Sept 28, 2022, 442 participants were enrolled from 44 households. The median age was 15 years (IQR 6-28) and 233 (53%) were female. We identified 17 pharyngitis and 99 pyoderma events and 49 pharyngeal and 39 skin S pyogenes carriage acquisition events. Mean monthly prevalence was 1·4% (95% CI 1·1-1·9) for S pyogenes pharyngeal carriage and 1·2% (0·9-1·6) for S pyogenes skin carriage. Incidence was 120 per 1000 person-years (95% CI 87-166) for S pyogenes pharyngeal carriage, 124 per 1000 person-years (90-170) for S pyogenes skin carriage, 51 per 1000 person-years (31-84) for S pyogenes pharyngitis, and 263 per 1000 person-years (212-327) for S pyogenes pyoderma. Pharyngeal carriage risk was higher during the rainy season (HR 5·67, 95% CI 2·19-14·69) and in larger households (per additional person: 1·03, 1·00-1·05), as was pharyngitis risk (rainy season: 3·00, 1·10-8·22; household size: 1·04, 1·02-1·07). Skin carriage risk was not affected by season or household size, but was lower in female than in male participants (0·45, 0·22-0·92) and highest in children younger than 5 years compared with adults (22·69, 3·08-167·21), with similar findings for pyoderma (female sex: 0·34, 0·19-0·61; age <5 years: 7·00, 2·78-17·64). Median clearance time after carriage acquisition was 4·0 days for both skin (IQR 3·5-7·0) and pharynx (3·5-7·3). The mean household secondary attack rate was 4·9 (95% CI 3·5-6·3) for epidemiologically linked S pyogenes events and 0·74 (0·3-1·2) for emm-linked S pyogenes events. Of the 204 carriage and disease events, emm types were available for 179 (88%). Only 18 emm-linked between-visit household transmission events were identified. Pyoderma was the most common source of S pyogenes household transmissions in 11 (61%) of 18 emm-linked transmissions. Both pharynx to skin and skin to pharynx transmission events were observed.
CONCLUSIONS: S pyogenes carriage and infection are common in The Gambia, particularly in children. Most events are non-household acquisitions, but skin carriage and pyoderma have an important role in S pyogenes household transmission and bidirectional transmission between skin and pharynx occurs.
BACKGROUND: Wellcome Trust, Chadwick Trust, Fonds National de la Recherche Scientifique (Belgium), European Society for Paediatric Infectious Diseases, and Medical Research Council (UK).

UNASSIGNED: Streptococcus pyogenes (StrepA) causes a significant burden of disease globally from superficial infections to invasive disease. It is responsible for over 500,000 deaths each year, predominantly in low- and middle-income countries (LMIC). Superficial StrepA infections of the skin and pharynx can lead to rheumatic heart disease, the largest cause of StrepA-related deaths in LMIC. StrepA can also asymptomatically colonise normal skin and the pharynx (carriage), potentially increasing infection risk. Streptococcus dysgalactiae subsp. equisimilis (SDSE) carriage is also common in LMIC and may interact with StrepA. This study aims to investigate StrepA and SDSE carriage and infection epidemiology, transmission dynamics and naturally acquired immunity within households in The Gambia.
UNASSIGNED: A longitudinal household observational cohort study will be conducted over one year. 45 households will be recruited from the urban area of Sukuta, The Gambia, resulting in approximately 450 participants. Households will be visited monthly, and available participants will undergo oropharyngeal and normal skin swabbing. Incident cases of pharyngitis and pyoderma will be captured via active case reporting, with swabs taken from disease sites. Swabs will be cultured for the presence of group A, C and G beta-haemolytic streptococci. Isolates will undergo whole genome sequencing. At each visit, clinical, socio-demographic and social mixing data will be collected. Blood serum will be collected at baseline and final visit. Oral fluid and dried blood spot samples will be collected at each visit. Mucosal and serum anti-StrepA antibody responses will be measured.
UNASSIGNED: This study will report StrepA and SDSE clinical epidemiology, risk factors, transmission dynamics, and serological responses to carriage and infection. Detailed social mixing behaviour will be combined with phylogenetic relatedness to model the extent of transmission occurring withing and between households. The study will provide data to help meet global strategic StrepA research goals.

Staphylococcus pseudintermedius is the most common opportunistic pathogen in dogs and methicillin resistance (MRSP) has been identified as an emerging problem in canine pyoderma. Here, we evaluated the antimicrobial resistance (AMR) features and phylogeny of S. pseudintermedius isolated from canine pyoderma cases in Argentina (n = 29) and the United States (n = 29). 62% of isolates showed multi-drug resistance. The AMR genes found: mecA, blaZ, ermB, dfrG, catA, tetM, aac(6\')-aph(2″), in addition to tetK and lnuA (only found in U.S. isolates). Two point mutations were detected: grlA(S80I)-gyrA(S84L), and grlA(D84N)-gyrA(S84L) in one U.S. isolate. A mutation in rpoB (H481N) was found in two isolates from Argentina. SCCmec type III, SCCmec type V, ΨSCCmec57395 were identified in the Argentinian isolates; and SCCmec type III, SCCmec type IVg, SCCmec type V, and SCCmec type VII variant in the U.S. cohort. Sequence type (ST) ST71 belonging to a dominant clone was found in isolates from both countries, and ST45 only in Argentinian isolates. This is the first study to comparatively analyze the population structure of canine pyoderma-associated S. pseudintermedius isolates in Argentina and in the U.S. It is important to maintain surveillance on S. pseudintermedius populations to monitor AMR and gain further understanding of its evolution and dissemination.

Increased antimicrobial resistance highlights the need for alternatives to antibiotics. Bacteriophages, which are benign viruses that kill bacteria, are promising. We studied the efficacy of topical bacteriophages for treating equine staphylococcal superficial pyodermas. Eight Staphylococcus aureus isolates were tested against a bacteriophage bank, and a cocktail consisting of two bacteriophages was prepared. Twenty horses with clinical and cytological evidence of superficial pyoderma and confirmed S. aureus infection based on swabbed culture were enrolled in the study. Each horse received both the bacteriophage cocktail and the placebo at two different infection sites, once daily for four weeks. Clinical lesions and cytology were evaluated weekly by an investigator who was unaware of the treatment sites. All infection sites were swabbed and cultured at the end of the study. A linear mixed model showed no significant differences between the placebo and treatment sites in terms of clinical signs, cytological scores of inflammation, and bacterial counts at the end of the study. It is possible that the bacteriophage cocktail killed S. aureus, but cytology scores did not change as new populations of cocci took over. The study limitations included a small sample size and inconsistent control of the underlying causes of pyodermas.

There is little currently little information available regarding the nature of the advice requests veterinary dermatologists receive from general practitioners. Collation of such data could direct continuing veterinary development in the future.
Dermatologists completed hand-written recording sheets during or after enquiries. Information recorded included the route of enquiry, nature of advice, material provided, practice type and location, animal signalment, presenting signs, diagnosis/differential diagnosis, treatment and referral recommendations, time taken and if charges were made.
Twelve dermatology services recorded 768 advice requests over a 6-month period. Most requests were submitted via email and related to canine dermatology (81%). An average of 9.5 minutes was spent replying to requests. Charges were made in 2% of cases. Advice regarding otitis was most commonly sought, followed by pruritus, alopecia and crusting. The most frequently discussed diagnoses included allergy, otitis, pyoderma, demodicosis, dermatophytosis and neoplasia. Antibiotics, anti-pruritics and topical otic medications were the most commonly discussed therapeutics.
This is an initial study and therefore there are limitations involving the depth of the data. Additional studies should be completed which identify why advice is sought, decision-making regarding referral, and if advice should be charged similarly to other disciplines.
These findings highlight that veterinarians mostly frequently seek advice on management of common dermatological problems, including allergy, otitis and pyoderma.

BACKGROUND: Rifampicin (RFP) is a potential treatment for canine multidrug-resistant (MDR) meticillin-resistant staphylococci (MRS), yet the use of lower doses based on recent MIC data has not been evaluated in vivo.
OBJECTIVE: To provide information on the efficacy and safety of low-dose range RFP (≤6 mg/kg/day) for the treatment of canine MDR MRS pyoderma.
METHODS: Fifty-one client-owned dogs.
METHODS: Retrospective review of dogs medical records. Dogs were from 11 US dermatology referral practices and had oral RFP at ≤6 mg/kg/day. Data evaluated included response to treatment, adverse events, and serum changes in alanine aminotransferase (ALT) and alkaline phosphatase (ALP).
RESULTS: Complete resolution of pyoderma occurred in 39 of 51 dogs (76.5%). Topical antimicrobials were used concurrently in most cases (47 of 51; 92.2%). ALP elevation >1.5-fold of baseline or the high end of the reference range occurred in nine of 37 (24.3%) dogs, while ALT elevation above baseline and the high end of the reference range occurred in two of 36 (5.6%). Only six of 51 (11.8%) had clinical adverse events during treatment; five of six (83.3%) were mild reactions consisting of lethargy and gastrointestinal signs, while one dog had a possible cutaneous adverse drug reaction. Of those that experienced clinical adverse events, four of six (66.7%) did not have concurrent increased liver enzyme activity, while two of six (33.3%) had elevations in ALP alone.
CONCLUSIONS: Low-dose RFP (≤6 mg/kg/day) appears to be a relatively safe and effective single-agent systemic antibiotic in combination with topical antimicrobials for canine MDR MRS pyoderma.
BACKGROUND: La rifampicine (RFP) est un traitement potentiel des staphylocoques canins multirésistants (MDR) résistants à la méticilline (MRS), mais l\'utilisation de doses plus faibles sur la base de données récentes sur la CMI n\'a pas été évaluée in vivo. Hypothèse/Objectifs : Fournir des informations sur l\'efficacité et l\'innocuité des RFP à faible dose (≤ 6 mg/kg/jour) pour le traitement de la pyodermite MDR-MR canine. Animaux : Cinquante et un chiens de propriétaires. Matériels et méthodes : Revue rétrospective de chiens ayant reçu RFP par voie orale à des doses ≤ 6 mg/kg/jour provenant des dossiers médicaux de 11 centres de référés en dermatologie aux États-Unis. Les données évaluées comprenaient la réponse au traitement, les événements indésirables et les modifications sériques de l\'alanine aminotransférase (ALT) et de la phosphatase alcaline (ALP). Résultats : Une résolution complète de la pyodermite s\'est produite chez 39 des 51 chiens (76,5 %). Des antimicrobiens topiques ont été utilisés simultanément dans la plupart des cas (47 sur 51 ; 92,2 %). Une élévation de l\'ALP> 1,5 fois la ligne de base ou l\'extrémité supérieure de la plage de référence s\'est produite chez neuf des 37 (24,3%) chiens, tandis qu\'une élévation de l\'ALT au-dessus de la ligne de base et de l\'extrémité supérieure de la plage de référence s\'est produite chez deux des 36 (5,6%). Seuls six sur 51 (11,8 %) ont eu des événements indésirables cliniques pendant le traitement ; cinq des six (83,3 %) étaient des réactions bénignes consistant en une léthargie et des signes gastro-intestinaux, tandis qu\'un chien a eu un possible effet indésirable cutané au médicament. Parmi ceux qui ont subi des événements indésirables cliniques, quatre sur six (66,7 %) n\'ont pas eu d\'augmentation simultanée de l\'activité des enzymes hépatiques, tandis que deux sur six (33,3 %) ont présenté des élévations de l\'ALP seule. Conclusions et pertinence clinique : La RFP à faible dose (≤ 6 mg/kg/jour) semble être un antibiotique systémique à agent unique relativement sûr et efficace en association avec des antimicrobiens topiques pour la pyodermite MDR MRS canine.
Introducción- la rifampicina (RFP) es un tratamiento potencial para los estafilococos resistentes a múltiples fármacos (MDR) y meticilina (MRS), sin embargo, el uso de dosis más bajas basado en datos recientes de MIC no se ha evaluado in vivo. Hipótesis/Objetivos- Proporcionar información sobre la eficacia y seguridad de RFP en el rango de dosis bajas (≤6 mg/kg/día) para el tratamiento de la pioderma canina MDR MRS. Animales- Cincuenta y un perros propietarios particulares. Materiales y métodos- revisión retrospectiva de perros que recibieron RFP oral a dosis ≤6 mg/kg/día obtenida de historiales clínicos de 11 prácticas de referencia de dermatología de los Estados Unidos. Los datos evaluados incluyeron la respuesta al tratamiento, los eventos adversos y los cambios séricos en la alanina aminotransferasa (ALT) y la fosfatasa alcalina (ALP). Resultados- una resolución completa de la pioderma ocurrió en 39 de 51 perros (76,5 %). Antimicrobianos tópicos se usaron al mismo tiempo en la mayoría de los casos (47 de 51; 92,2%). En nueve de 37 (24,3 %) perros se produjo una elevación de ALP >1,5 veces respecto al valor inicial o el extremo superior del rango de referencia, mientras que en dos de 36 (5,6 %) se produjo una elevación de ALT por encima del valor inicial y en el límite superior del rango de referencia. Solo seis de 51 (11,8%) tuvieron eventos adversos clínicos durante el tratamiento; cinco de seis (83,3 %) fueron reacciones leves que consistieron en letargo y signos gastrointestinales, mientras que un perro tuvo una posible reacción cutánea adversa al medicamento. De los que experimentaron eventos adversos clínicos, cuatro de seis (66,7 %) no tuvieron un aumento simultáneo de la actividad de las enzimas hepáticas, mientras que dos de seis (33,3 %) tuvieron elevaciones en la ALP por sí sola. Conclusiones y relevancia clínica- la dosis baja de RFP (≤6 mg/kg/día) parece ser un antibiótico sistémico de uso único relativamente seguro y efectivo en combinación con antimicrobianos tópicos para la pioderma canina MDR MRS.
Hintergrund: Rifampicin (RFP) ist eine mögliche Behandlung für multi-resistente (MDR) Methicillin-resistente Staphylokokken (MRS) des Hundes, wobei allerdings der Einsatz niedrigerer Dosen basierend auf jüngsten MIC Daten bis jetzt noch nicht in vivo evaluiert wurden. Hypothese/Ziele: Informationen zu liefern in Bezug auf die Wirksamkeit und die Sicherheit von niedrig-dosiertem RFP (≤6 mg/kg/Tag) zur Behandlung der MDR MRS Pyodermie des Hundes. Tiere: Einundfünfzig Hunde in Privatbesitz Material und Methoden: Es handelt sich hierbei um eine retrospektive Review von Hunden, die RFP bei einer Dosierung von ≤6 mg/kg/Tag per os erhielten; diese wurden aus den Patientenkarteien von 11 dermatologischen Überweisungspraxen in den Vereinigten Staaten herausgesucht. Die Daten, die evaluiert wurden, betrafen Antwort auf die Behandlung, Nebenwirkungen, Serumveränderungen der Alanin Aminotransferase (ALT) und der alkalischen Phosphatase (ALP). Ergebnisse: Eine komplette Abheilung der Pyodermie erfolgte in 39 von 51 Hunden (76,5%). Topische antimikrobielle Substanzen wurden in den meisten Fällen (47 von 51; 92,2%) gleichzeitig angewendet. Eine ALP Erhöhung auf das 1,5-fache der Ausgangsbasis oder dem oberen Rand der Referenzwerte erfolgte in neun von 37 (24,3%) der Hunde während ALT Erhöhungen über den Ausgangswert und das obere Limit des Referenzwertes nur bei zwei von 36 (5,6%) Hunden auftrat. Nur sechs von 51 (11,8%) zeigten klinische Nebenwirkungen während der Behandlung; fünf von sechs (83,3%) zeigten milde Reaktionen, die aus Lethargie und gastrointestinalen Beschwerden bestanden, während ein Hund eine mögliche kutane Nebenwirkungsreaktion zeigte. Von jenen Hunden, die klinische Nebenwirkungen zeigten, hatten vier von sechs (66,7%) keine bleibenden erhöhten Leberwerte, während zwei von sechs (33,3%) nur eine erhöhte ALP zeigten. Schlussfolgerungen und klinische Bedeutung: RFP niedrig dosiert (≤6 mg/kg/Tag) in Kombination mit topischen antimikrobiellen Substanzen scheint eine relativ sichere und wirksame Methode zu sein, um mit einem einzigen Antibiotikum die MDR MRS Pyodermie des Hundes systemisch zu behandeln.
背景- リファンピシン(RFP)は犬の多剤耐性(MDR)メチシリン耐性ブドウ球菌(MRS)に対する治療薬として期待されているが，最近のMICデータに基づく低用量の使用はin vivoでは評価されていない。 仮説/目的- 本研究の目的は、犬のMDR MRS膿皮症に対する低用量域RFP(≦6 mg/kg/day)の有効性および安全性に関する情報を提供することであった。 供試動物- オーナー所有犬 51 頭。 材料と方法- 米国11カ所の皮膚科紹介施設の診療記録から入手した、6mg/kg/day以下の用量のRFPを経口投与された犬の回顧的レビュー。評価したデータは、治療に対する反応、有害事象、アラニンアミノトランスフェラーゼ(ALT)およびアルカリホスファターゼ(ALP)の血清変化などである。 結果 51頭中39頭(76.5%)で膿皮症は完治した。ほとんどの症例で外用抗菌薬が併用された(51頭中47頭，92.2%)。ALPが基準値の1.5倍以上または基準値の上限を超えたのは37頭中9頭(24.3%)、ALTが基準値の上限を超えたのは36頭中2頭(5.6%)であった。臨床的有害事象は51頭中6頭(11.8%)に発現し，6頭中5頭(83.3%)が嗜眠や消化器症状からなる軽度の反応であり，1頭が皮膚の副作用の可能性があった。また，臨床的有害事象のうち，6頭中4頭(66.7%)は肝酵素活性の上昇を同時に認めず，6頭中2頭(33.3%)はALPのみの上昇を認めた。 結論と臨床的関連性 犬のMDR型MRS膿皮症に対する低用量RFP(≦6 mg/kg/day)は，外用抗菌薬との併用で比較的安全かつ有効な単剤全身用抗菌薬と思われた。.
背景:利福平 (RFP) 是治疗犬多重耐药 (MDR) 耐甲氧西林葡萄球菌 (MRS) 的潜在药物，但基于最近的 MIC 数据，尚未评价在体内较低剂量的使用。 假设/目的:提供低剂量范围RFP(≤6 mg/kg/天)治疗犬 MDR MRS 脓皮病的疗效和安全性信息。 动物:51只私家犬。 材料和方法:回顾性审查接受剂量≤6 mg/kg/天 RFP 经口给药的犬，来自11家美国皮肤科转诊诊所的病历。评价的数据包括治疗效果、不良反应和血清丙氨酸氨基转移酶 (ALT) 和碱性磷酸酶 (ALP) 变化。 结果:51只犬中有39只 (76.5%) 的脓皮病完全消退。大多数病例同时使用外部抗菌剂 (47/51；92.2%)。37只犬中有9只 (24.3%) 发生 ALP 升高 > 1.5倍基线值或参考范围上限，而36只犬中有2只 (5.6%) 发生 ALT 升高高于基线值和参考范围上限。治疗期间，51只犬中仅6只 (11.8%) 发生临床不良反应；6只犬中的5只 (83.3%) 为轻度反应，包括嗜睡和胃肠道症状，而1只犬可能发生皮肤药物不良反应。在发生临床不良反应的犬中，6例中的4例 (66.7%) 未同时发生肝酶活性升高，而6例中的2例 (33.3%) 仅发生 ALP 升高。.
Contexto - A rifampicina (RFP) é um tratamento potencial para estafilococos resistentes à meticilina (MRS) multirresistentes (MDR) e a utilização de doses mais baixas baseado em dados recentes de MIC não foi avaliada in vivo. Hipótese/Objetivos: Fornecer informações sobre a eficácia e segurança de RFP em menor dosagem (≤6 mg/kg/dia) para o tratamento de piodermite canina por MRS MDR. Animais: Cinquenta e um cães de clientes. Materiais e métodos: Uma revisão retrospectiva dos prontuários de cães que receberam RFP oral na dose de ≤6 mg/kg/dia em 11 clínicas dermatológicas nos Estados Unidos. Os dados avaliados incluíram resposta ao tratamento, eventos adversos, alterações séricas de alanina aminotransferase (ALT) e fosfatase alcalina (FA). Resultados: Resolução completa da piodermite ocorreu em 39 de 51 dos cães (76,5%). Antimicrobianos tópicos foram utilizados concomitantemente na maioria dos casos (47 de 51; 92,2%). Elevação de mais de 1,5 vezes na FA ou para o limite superior do intervalo de referência ocorreu em nove de 37 cães (24,3%), enquanto a elevação de ALT acima do valor inicial e o limite superior do valor de referência ocorreu em dois de 36 (5,6%). Apenas cinco de 51 (11,8%) apresentaram efeitos adversos durante o tratamento; cinco de seis (83,3%) tiveram reações leves caracterizadas por letargia e sinais gastrointestinais, enquanto um cão apresentou uma possível farmacodermia. Dos que apresentaram eventos adversos, quatro de seis (66,7%) não apresentaram aumento concomitante de enzimas hepáticas, enquanto dois de seis (33,3%) tiveram aumento de FA isoladamente. Conclusões e relevância clínica - RFP em baixa dosagem (≤6 mg/kg/dia) aparenta ser relativamente segura e eficaz em monoterapia no tratamento da piodermite canina por MRS MDR por via sistêmica, associada a antimicrobianos tópicos.

BACKGROUND: Topical treatments can be beneficial for managing canine superficial pyoderma. A novel antiseptic agent, olanexidine gluconate, has become available recently for use in humans, and its efficacy for canine pyoderma as topical therapy is unknown.
OBJECTIVE: The antimicrobial effect of olanexidine was evaluated using minimal inhibitory concentration (MIC) towards Staphylococcus pseudintermedius. Furthermore, its clinical efficacy in canine superficial pyoderma was assessed in a randomized, single-blinded study.
METHODS: Twenty-eight client-owned dogs with atopic dermatitis and superficial pyoderma.
METHODS: The MIC of olanexidine was determined for S. pseudintermedius isolates (n=73) by serial dilution of 96-well broth microdilution method. Regarding the clinical trial, all recruited dogs were randomized into two groups; one treated with 1.5% olanexidine spray once daily and the other with a 3% chlorhexidine shampoo once a week for 2 times, respectively. Clinical assessment was performed at days 0 and 14 according to the guidelines of the Japanese Society of Antimicrobials for Animals.
RESULTS: The MIC values for methicillin-resistant S. pseudintermedius (MRSP) and methicillin-sensitive S. pseudintermedius (MSSP) were 0.23 μg/ml and 0.24 μg/ml (P =0.9), respectively. In clinical trial, olanexidine and chlorhexidine showed substantial improvement in clinical presentation compared to the baseline.
CONCLUSIONS: Olanexidine showed comparable efficacy to chlorhexidine (P=0.73). Moreover, the MIC against S. pseudintermedius indicated high bactericidal activity, which was supported by the topical effectiveness of olanexidine.
UNASSIGNED: Les traitements topiques peuvent être bénéfiques pour la gestion de la pyodermite superficielle canine. Un nouvel agent antiseptique, le gluconate d\'olanexidine, est devenu disponible récemment pour une utilisation chez l\'homme, et son efficacité pour la pyodermite canine en tant que thérapie topique est inconnue.
UNASSIGNED: L\'effet antimicrobien de l\'olanexidine a été évalué en utilisant la concentration minimale inhibitrice (CMI) contre Staphylococcus pseudintermedius. De plus, son efficacité clinique dans la pyodermite superficielle canine a été évaluée dans une étude randomisée en simple aveugle.
UNASSIGNED: Vingt-huit chiens appartenant à des clients atteints de dermatite atopique et de pyodermite superficielle. MATÉRIELS ET METHODS: La CMI de l\'olanexidine a été déterminée pour les isolats de S. pseudintermedius (n = 73) par dilution en série de la méthode de microdilution en bouillon à 96 puits. Concernant l\'essai clinique, tous les chiens recrutés ont été randomisés en deux groupes ; respectivement, l\'un était traité avec un spray d\'olanexidine à 1,5% une fois par jour et l\'autre avec un shampoing à la chlorhexidine à 3% une fois par semaine à deux reprises. L\'évaluation clinique a été réalisée aux jours 0 et 14 selon les directives de la Société japonaise des antimicrobiens pour les animaux. RÉSULTATS: Les valeurs de CMI pour S. pseudintermedius résistant à la méticilline (MRSP) et S. pseudintermedius sensible à la méticilline (MSSP) étaient respectivement de 0,23 g/ml et 0,24 μg/ml (P = 0,9). Dans les essais cliniques, l\'olanexidine et la chlorhexidine ont montré une amélioration substantielle de la présentation clinique par rapport aux données de base.
UNASSIGNED: L\'olanexidine a montré une efficacité comparable à la chlorhexidine (P=0,73). De plus, la CMI contre S. pseudintermedius indiquait une activité bactéricide élevée, qui était soutenue par l\'efficacité topique de l\'olanexidine.
INTRODUCCIÓN: los tratamientos tópicos pueden ser beneficiosos para controlar la pioderma superficial canina. Un nuevo agente antiséptico, el gluconato de olanexidina, se ha aprobado recientemente para su uso en humanos, y se desconoce su eficacia para la pioderma canina como terapia tópica. OBJETIVO: se evaluó el efecto antimicrobiano de olanexidina utilizando la concentración inhibitoria mínima (MIC) frente Staphylococcus pseudintermedius. Además, su eficacia clínica en la pioderma superficial canina se evaluó en un estudio al azar, simple ciego. ANIMALES: veintiocho perros propietarios particulares con dermatitis atópica y pioderma superficial. MÉTODOS Y MATERIALES: la MIC de olanexidina se determinó para aislados de S. pseudintermedius (n = 73) mediante dilución en serie con el método de microdilución en caldo de 96 pocillos. Con respecto al ensayo clínico, todos los perros seleccionados fueron asignados al azar en dos grupos; uno tratado con un aerosol de olanexidina al 1,5% una vez al día y el otro con un champú de clorhexidina al 3% una vez a la semana 2 veces, respectivamente. La evaluación clínica se realizó los días 0 y 14 de acuerdo con las directrices de la Sociedad Japonesa de Antimicrobianos para Animales. RESULTADOS: los valores de MIC para S. pseudintermedius resistente a meticilina (MRSP) y S. pseudintermedius sensible a meticilina (MSSP) fueron de 0,23 μg / ml y 0,24 μg / ml (P = 0,9), respectivamente. En un ensayo clínico, la olanexidina y la clorhexidina mostraron una mejora sustancial en la presentación clínica en comparación con la línea de base. CONCLUSIONES E IMPORTANCIA CLÍNICA: la olanexidina mostró una eficacia comparable a la clorhexidina (p = 0,73). Además, la MIC frente a S. pseudintermedius indicó una alta actividad bactericida, que fue apoyada por la eficacia tópica de olanexidina.
UNASSIGNED: Topische Behandlungen können sich beim Management der superfiziellen Pyodermie des Hundes günstig auswirken. Ein neuer antiseptischer Wirkstoff, Olanexidin Gukonat, steht in der letzten Zeit für die Verwendung beim Menschen zur Verfügung. Seine Wirksamkeit bei caniner Pyodermie als topische Therapie ist unbekannt. ZIEL: Die antimikrobielle Wirkung von Olanexidin wurde mittels minimaler Hemmstoffkonzentration (MIC) gegenüber Staphylococcus pseudintermedius evaluiert. Weiters wurde seine klinische Wirksamkeit bei caniner superfizieller Pyodermie in einer randomisierten Einfachblindstudie untersucht.
UNASSIGNED: Achtundzwanzig Hunde in Privatbesitz mit atopischer Dermatitis und superfizieller Pyodermie.
UNASSIGNED: Die MIC Werte für Methicillin-resistenten S. pseudintermedius (MRSP) und Methicillin-sensiblen S. pseudintermedius (MSSP) betrugen 0,23 µg/ml bzw 0,24 µg/ml (P =0,9). Im klinischen Versuch zeigten Olanexidin und Chlorhexidin im Vergleich zur Ausgangsbasis eine deutliche Verbesserung bei der klinischen Präsentation.
UNASSIGNED: Olanexidin zeigte eine mit Chlorhexidin vergleichbare Wirksamkeit (P=0,73). Darüber hinaus wies die MIC gegenüber S. pseudintermedius auf eine hohe bakterizide Aktivität hin, was durch die oberflächliche Wirksamkeit von Olanexidin unterstützt wird.
背景: 犬の表在性膿皮症の管理には，外用療法が有効である。新規消毒薬であるOlanexidine gluconateオラネキシジングルコン酸塩は、近年、ヒトに使用できるようになったが、犬の膿皮症に対する外用療法としての有効性は不明である。 目的: オラネキシジンの抗菌効果をStaphylococcus pseudintermediusに対する最小発育阻止濃度（MIC）を用いて評価した。さらに、犬の表在性膿皮症に対する臨床的有効性をランダム化単盲検試験で評価した。 供試動物: アトピー性皮膚炎および表在性膿皮症を有する28頭のオーナー所有犬を対象とした。 材料・方法: S. pseudintermedius分離株（n=73）に対するオラネキシジンのMICは、96ウェルブロス微量希釈法による連続希釈で決定した。臨床試験については、募集した全犬を無作為に2群に分け、一方には1.5％オラネキシジンスプレーを1日1回投与し、他方には3％クロルヘキシジンシャンプーを週1回、2回投与した。臨床評価は、日本動物用抗菌薬学会のガイドラインに従って、0日目と14日目に行った。 結果: チシリン耐性S. pseudintermedius（MRSP）およびメチシリン感受性S. pseudintermedius（MSSP）のMIC値は，それぞれ0.23 μg/mlおよび0.24 μg/ml（P = 0.9）であった。臨床試験において、オラネキシジンおよびクロルヘキシジンはベースラインに比べて臨床症状の大幅な改善を認めた。 結論および臨床上の重要性: オラネキシジンは，クロルヘキシジンと同等の効果を示した（P＝0.73）。さらに、S. pseudintermediusに対するMICは高い殺菌力を示し、オラネキシジンの局所的な有効性に裏付けられていた。.
背景: 外部治疗可能有益于管理犬浅表脓皮病。一种新型抗菌剂奥兰西丁最近可用于人，其作为外部治疗对犬脓皮病的疗效尚不清楚。 目的: 通过对假中间型葡萄球菌的最小抑菌浓度(MIC)，评价奥兰西丁的抗菌作用。此外，在一项随机、单盲研究中，评估其在犬浅表脓皮病中的临床有效性。 动物: 28只患有特应性皮炎和浅表脓皮病的宠物犬。 方法和材料: 通过96孔微量肉汤稀释法的系列稀释，测定假中间型葡萄球菌分离株(n = 73)的奥兰西丁 MIC。临床试验中，所有招募的犬被随机分为两组；一组接受1.5%奥兰西丁喷雾剂，每日一次治疗，另一组接受3%氯己定香波每周一次治疗，连续2次。根据日本动物抗菌剂协会的指导原则，在第0天和第14天进行临床评估。 结果: 对耐甲氧西林假中间型葡萄球菌(MRSP)和甲氧西林敏感假中间型葡萄球菌(MSSP)的MIC值分别为0.23 μg/mL和0.24 μg/mL(P = 0.9)。在临床试验中，与基线相比，奥兰西丁和氯己定均显示出实质性临床改善。 结论和临床重要性: 奥兰西丁与氯己定的疗效相当(P = 0.73)。此外，对假中间型葡萄球菌的MIC显示出较高的杀菌活性，这证实了奥兰西丁外部治疗的有效性。.
INTRODUÇÃO: Os tratamentos tópicos podem ser benéficos para o manejo da piodermite superficial canina. Um novo agente anti-séptico, gluconato de olanexidina, tornou-se recentemente disponível para uso em humanos, e sua eficácia para piodermite canina como terapia tópica é desconhecida.
UNASSIGNED: O efeito antimicrobiano da olanexidina foi avaliado através da concentração inibitória mínima (MIC) para Staphylococcus pseudintermedius. Além disso, sua eficácia clínica na piodermite superficial canina foi avaliada em um estudo randomizado simples-cego.
UNASSIGNED: Vinte e oito cães de clientes com dermatite atópica e piodermite superficial. MÉTODOS E MATERIAIS: A MIC de olanexidina foi determinada para isolados de S. pseudintermedius (n=73) por diluição em série utilizando o método de microdiluição em caldo com 96 poços. Em relação ao ensaio clínico, todos os cães recrutados foram divididos aleatoriamente em dois grupos; um grupo foi tratado com spray de olanexidina 1,5% uma vez ao dia e o outro com xampu de clorexidina 3% uma vez por semana por 2 vezes, respectivamente. A avaliação clínica foi realizada nos dias 0 e 14 de acordo com as diretrizes da Sociedade Japonesa de Antimicrobianos para Animais.
UNASSIGNED: Os valores de MIC para S. pseudintermedius resistente à meticilina (MRSP) e S. pseudintermedius sensível à meticilina (MSSP) foram 0,23 μg/ml e 0,24 μg/ml (P=0,9), respectivamente. No ensaio clínico, a olanexidina e a clorexidina demonstraram melhora significativa na apresentação clínica em comparação ao tempo zero. CONCLUSÕES E IMPORTÂNCIA CLÍNICA: Olanexidina demonstrou eficácia comparável à clorexidina (P=0,73). Além disso, a MIC contra S. pseudintermedius indicou alta atividade bactericida, concordando com a eficácia tópica da olanexidina.

Abstract  Twenty-five pure-bred and two cross-bred German Shepherd dogs with German Shepherd dog pyoderma (GSP) were treated with enrofloxacin as an antimicrobial therapy. Following 28 weeks of treatment at a dose rate of 5 mg kg-1 , administered orally once daily, excellent results were obtained in 23 dogs (85.2%), and fair results in three dogs (11.1%). One dog (3.7%) showed no response. These findings indicate that enrofloxacin therapy is an effective antimicrobial treatment for the bacterial infection in GSP. Resumé  25 Bergers Allemandes de pure race et 2 métis suffrant d\'infection bactérienne de type pyodermite du Berger Allemand fürent traités à l\'aide d\'enrofloxacine comme antimicrobien. Deux à huit semaines de traitment à la dose de 5 mg kg-1 per os une fois par jour donnèrent un excellent resultat chez 23 chiens (85.2%), et une amelioration dans 3 cas (11.1%). Un chien (3.7%) ne répondit pas du tout. Ces résultats montrent que l\'enrofloxacine est efficace en tant qu\'antibactérien dans le traitment de la pyodermite du Berger Allemand. [Koch, H-J., Peters, S. Antimicrobial Therapy in German Shepherd Dog Pyoderma (GSP). An open clinical study. (Traitment anti-infectieux de la pyodermite du Berger Allemand. Etude clinique ouverte). Veterinary Dermatology 1996; 7: 177-181.] Resumen  25 perros pastor alemán de pura raza y dos mezcla de pastor alemán que tenian pioderma fueron tratados con enrofloxacina. Después de 2-8 semanas de tratamiento a una dosis de 5 mg kg-1 por via oral una vez al día, se obtuvieron resultados excelentes en 23 perros y resultados moderados en 3 perros. Un perro no respondió. Estos resultados muestran que enrofioxacina es un tratamiento efectivo contra pioderma de pastor alemán. [Koch, H-J., Peters, S. Antimicrobial Therapy in German Shepherd Dog Pyoderma (GSP). An open clinical study. (Terapia antimicrobiana en perros de pastor alemán. Un estudio clinico). Veterinary Dermatology 1996; 7: 177-181.] Zusammenfassung- 25 reinrassige Deutsche Schäferhunde und zwei Deutsche Schäferhund-Mischlinge mit bakterieller Infektion infolge Schäferhundpyodermie wurden mit Enrofloxacin antimikrobiell behandelt. Nach zwei-bis achtwöchiger Behandlung in der Dosierung von 5 mg kg-1 Körpergewicht, 1 × tgl. oral verabreicht, wurden bei 23 Hunden (85, 2%) sehr gute und bei drei Hunden (11, 1%) befriedigende Behandlungsergebnisse erzielt. Ein Hund (3, 7%) sprach nicht auf die Behandlung an. Die vorliegenden Ergebnisse zeigen, daß Enrofloxacin zur erfolgreichen antimikrobiellen Behandlung der bakteriellen Infektion bei der Schäferhundpyodermie geeignet ist. [Koch, H-J., Peters, S. Antimicrobial Therapy in German Shepherd Dog Pyoderma (GSP). An open clinical study. (Antimikrobielle Therapie bei Deutscher Schäferhundpyodermie (DSP). Eine klinische offene Untersuchung). Veterinary Dermatology 1996; 7: 177-181.].

UNASSIGNED: Staphylococci are the most common cause of pyoderma in dogs.
UNASSIGNED: The purpose of the present study was to investigate clinical, bacteriological and histopathological aspects of bacterial skin infections in a population of Iranian domestic dogs with first-time pyoderma.
UNASSIGNED: The study animals were 61 clinical cases of Iranian domestic dogs with first-time pyoderma. The diagnosis of pyoderma was based on the history, the presence of variable gross cutaneous lesions, positive findings on microscopic examination of surface cytology and histopathological findings.
UNASSIGNED: Detection of pyoderma amongst adult dogs was significantly higher than puppies (P=0.001). Large breed dogs were presented more frequently for pyoderma in comparison to small breeds (P=0.002). Bacterial species were recovered from 43 of the 61 (70.49%) studied animals. No isolates were recovered from 18 studied dogs. The most frequently recovered bacterial genus was Staphylococcus (32/43 isolates, 74.41%) including: S. epidermidis (22/43 isolates, 51.16%), S. aureus (7/43 isolates, 16.27%), and S. pseudintermedius (3/43 isolates, 6.97%). Staphylococci species resistance was most commonly seen against amoxicillin (94.11%), penicillin (83.35%), and ampicillin (76.47%). Resistant to cephalexin and cefoxitin was 5.88% and 2.94%, respectively. A total of 27 of the staphylococci isolated (84.37%) were resistant to at least one antimicrobial agent and 19 isolates (59.37%) were resistant to three or more antimicrobial drugs.
UNASSIGNED: A better understanding of this microbial population is critical for clarification of the pathophysiology of bacterial skin diseases.

BACKGROUND: Canine pyoderma is a common skin infection caused predominantly by staphylococcal bacteria. Because of increasing rates of antimicrobial resistance in bacterial isolates, there is an urgent need for alternative or supplementary treatment options. W16P576, a Water Extract of Complex Mix of Edible Plants (WECMEP), has shown in vitro activity against a variety of bacteria, including Staphylococcus pseudintermedius. A canine model of pyoderma was developed which allows in vivo testing of antimicrobial agents in a controlled environment.
OBJECTIVE: To evaluate the antibacterial efficacy of topical application of W16P576 in a model of canine pyoderma.
METHODS: Nine laboratory housed beagle dogs.
METHODS: In an evaluator-blinded cross-over study with an eight week washout period, dogs were treated topically twice daily with W16P576 WECMEP or its vehicle, starting three days before bacterial challenge. On the day of challenge, each dog was treated with two concentrations of a clinical S. pseudintermedius strain on opposite sides of the body. Topical treatment was continued for 11 days and lesions of pyoderma were evaluated and scored for 14 days.
RESULTS: All dogs developed lesions consistent with bacterial pyoderma. Lesion scores were generally higher on the side inoculated with a higher concentration of bacteria. Treatment with W16P576 significantly reduced lesion development and hastened resolution of lesions, compared to placebo.
CONCLUSIONS: Topical application of W16P576 markedly reduced lesion development in this proof of principle study. Clinical trials are warranted to estimate benefits for dogs with naturally occurring pyoderma under field conditions.
UNASSIGNED: Die canine Pyodermie ist eine häufige Hautinfektion, die vor allem durch Staphylokokkenbakterien verursacht wird. Aufgrund der zunehmenden antimikrobiellen Resistenz von Bakterienisolaten, besteht eine dringende Notwendigkeit für Alternativen und unterstützende Therapieoptionen. W16P576, ein wässriger Extrakt aus einem komplexen Mix von essbaren Pflanzen (WECMEP), zeigt eine in vitro Aktivität gegenüber einer Vielzahl von Bakterien, zu denen auch Staphylococcus pseudintermedius zählte, gezeigt. Es wurde eine canines Modell für die Pyodermie entwickelt, welches in vivo Untersuchungen von antimikrobiellen Wirkstoffen in einer kontrollierten Umgebung ermöglicht. ZIEL: Eine Evaluierung der antibakteriellen Wirksamkeit der topischen Applikation von W16P576 in einem Modell der Pyodermie des Hundes.
UNASSIGNED: Neun Labor-Beagles.
UNASSIGNED: In einer Evaluierer-geblindeten cross-over Studie mit einer acht wöchigen Wash-out Periode wurden die Hunde zweimal täglich oberflächlich mit W16P576 WECMEP oder seinem Trägermedium behandelt, was drei Tage vor einer bakteriellen Provokation durchgeführt wurde. Am Tag der Provokation wurde jeder Hund mit zwei Konzentrationen eines klinischen S. pseudintermedius Stammes auf gegenüberliegenden Seiten des Körpers behandelt. Die topische Behandlung wurde 11 Tage lang weitergeführt und die Läsionen der Pyodermie evaluiert und 14 Tage lang bewertet.
UNASSIGNED: Alle Hunde entwickelten Läsionen, die mit einer bakteriellen Pyodermie im Einklang standen. Die Bewertungen der Läsionen waren generell schlechter auf der Seite, die mit einer höheren Bakterienkonzentration inokuliert worden war. Die Behandlung mit W16P576 reduzierte die Entstehung von Läsionen signifikant und förderte im Vergleich zu Plazebo die Heilung der Läsionen.
UNASSIGNED: Die topische Applikation von W16P576 reduzierte die Entstehung der Läsionen deutlich in dieser Proof-of-Principle Studie. Klinische Studien sind nötig, um die Vorteile für Hunde mit einer natürlich auftretenden Pyodermie unter Feldbedingungen zu erfassen.
背景: 犬脓皮病是一种常见的皮肤感染,主要由葡萄球菌引起。由于细菌耐药性的增加,迫切需要替代或补充治疗方案。W16P576是多种食用植物混合水提取物(WECMEP),已报道其对多种细菌具有体外活性,包括假中间型葡萄球菌。建立犬脓皮病模型,其允许在受控环境中活体测试抗菌药物。 目的: 评估外用W16P576在犬脓皮病模型中的抗菌效果。 动物: 实验室饲养的九只比格犬。 方法和材料: 在一项8周洗脱期的评估者盲法交叉研究中,从细菌攻毒前三天开始,每天用W16P576 WECMEP或其载体对犬进行每天两次的外部治疗。在每只犬的身体两侧用两种浓度的临床假中间型葡萄球菌进行攻毒。持续外部治疗11天,14天时评估脓皮病的病变并打分。 结果: 所有犬病变均与细菌性脓皮病一致。接种较高浓度细菌侧的病变评分普遍较高。与安慰剂相比,W16P576的治疗显著减慢了病变的发展,并加快了病变的消退。 结论: 在该原理验证研究中,外用W16P576可显著减慢病变的发展。有必要进行临床试验,来评估自然条件下对原发脓皮病患犬的疗效。.
BACKGROUND: La pyodermite canine est une infection cutanée fréquente, principalement causée par les staphylocoques. En raison de l\'augmentation des résistances antimicrobiennes des souches bactériennes, il y a un besoin urgent d\'options thérapeutiques alternatives ou supplémentaires. W16P576, un WECMEP (Water Extract of Complex Mix of Edible Plants), a montré son activité in vitro contre plusieurs bactéries, dont Staphylococcus pseudintermedius. Un modèle canin de pyodermite a été développé et permet des tests in vitro d\'agents antimicrobiens dans un environnement contrôlé.
OBJECTIVE: Evaluer l\'efficacité antibactérienne d\'une application topique de W16P576 dans un modèle de pyodermite canine.
UNASSIGNED: Neuf chiens beagle de laboratoire. MATÉRIELS ET MÉTHODES: Dans une étude croisée en aveugle avec une période de blanc de huit semaines, les chiens ont été traités par voie topique deux fois par jour avec W16P576 WECMEP ou son véhicule, trois jours avant exposition bactérienne. Le jour de la provocation, chaque chien a été traité avec deux concentrations de souches de S. pseudintermedius cliniques sur deux cotés opposés du corps. Le traitement topique a été poursuivi pendant 11 jours et les lésions de pyodermite évaluées et scorées pendant 14 jours. RÉSULTATS: Tous les chiens ont développé des lésions consistantes avec une pyodermite bactérienne. Les scores lésionnels étaient généralement plus élevés sur le coté inoculé avec une plus haute concentration bactérienne. Le traitement avec W16P576, comparé au placebo, diminuait significativement le développement des lésions et ont accéléré la résolution des lésions.
CONCLUSIONS: L\'application topique de W16P576 diminue le développement des lésions de façon marquée dans cette étude de preuve de concept. Les essais cliniques sont nécessaires pour déterminer les bénéfices pour les chiens avec des pyodermites naturelles sur le terrain.
背景: 犬膿皮症は、主にブドウ球菌が原因の一般的な皮膚感染症である。細菌分離株の抗菌薬耐性率が上昇しているため、代替または追加治療オプションを緊急的に必要としている。 食用植物の混合物の水抽出物(WECMEP)であるW16P576は、S. pseudintermediusを含むさまざまな細菌に対するin vitroでの活性を示している。制御された環境下での抗菌剤のin vivo試験を可能にする膿皮症の犬モデルが開発された。 目的: 本研究の目的は、犬膿皮症モデルに対しW16P576の外用適用による抗菌効果を評価することであった。 被験動物: 実験室に収容されたビーグル犬9頭。 材料と方法: 8週間のウォッシュアウト期間を設けた評価者盲検クロスオーバー試験では、細菌負荷の3日前に試験を開始し、W16P576 WECMEPまたはその媒体で犬を1日2回外用療法した。細菌負荷日に、各犬は、体の反対側を2種類の濃度の臨床S. pseudintermedius株で治療された。外用療法を11日間継続し、膿皮症の病変を評価し、14日間記録した。 結果: すべての犬は、細菌性膿皮症と一致する病変を発症した。病変スコアは、一般に、より高い濃度の細菌を接種した側でより高かった。 W16P576による治療は、プラセボと比較して、病変の発生を著しく減少させ、病変の消散を早めた。 結論: W16P576の外用適用により、本概念実証研究で病変の進展が著しく減少した。臨床試験は、野外条件下で自然に発生する膿皮症の犬の利益を推定するために保証されている。.
UNASSIGNED: A piodermite canina é uma infecção cutânea comum causada predominantemente por bactérias estafilocócicas. Devido ao aumento da frequência de resistência antimicrobiana em isolados bacterianos, há uma necessidade urgente de opções de tratamento alternativas ou suplementares. O W16P576, um extrato aquoso de um mix complexo de plantas comestíveis (WECMEP), demonstrou atividade in vitro contra uma variedade de bactérias, incluindo Staphylococcus pseudintermedius. Desenvolveu-se um modelo canino de piodermite que permite testes in vivo de agentes antimicrobianos em um ambiente controlado.
OBJECTIVE: Avaliar a eficácia antibacteriana da aplicação tópica de W16P576 em um modelo de piodermite canina.
UNASSIGNED: Nove cães beagle alojados em laboratório. MÉTODOS E MATERIAIS: Em um estudo cruzado, avaliador cego, com um intervalo de oito semanas, os cães foram tratados topicamente duas vezes ao dia com W16P576 WECMEP ou seu veículo, começando três dias antes do desafio bacteriano. No dia do desafio, cada cão foi tratado com duas concentrações de uma cepa clínica de S. pseudintermedius em lados opostos do corpo. O tratamento tópico foi continuado por 11 dias e as lesões de piodermite foram avaliadas e pontuadas por 14 dias.
RESULTS: Todos os cães desenvolveram lesões compatíveis com piodermite bacteriana. Os escores de lesão foram geralmente mais altos no lado inoculado com maior concentração de bactérias. O tratamento com W16P576 reduziu significativamente o desenvolvimento da lesão e acelerou a resolução das lesões, em comparação com o placebo. CONCLUSÃO: A aplicação tópica de W16P576 reduziu consideravelmente o desenvolvimento de lesões neste estudo de prova de princípio. Ensaios clínicos são necessários para avaliar os benefícios do tratamento em cães com piodermite natural em condições de campo.
INTRODUCCIÓN: la pioderma canina es una infección cutánea común causada predominantemente por bacterias estafilocócicas. Debido al aumento de las tasas de resistencia a los antimicrobianos en aislamientos bacterianos, existe una necesidad urgente de opciones de tratamiento alternativas o complementarias. W16P576, un extracto acuoso de una mezcla compleja de plantas comestibles (WECMEP), ha mostrado actividad in vitro frente a una variedad de bacterias, incluido Staphylococcus pseudintermedius. Se desarrolló un modelo canino de pioderma que permite la prueba in vivo de agentes antimicrobianos en un ambiente controlado. OBJETIVO: evaluar la eficacia antibacteriana de la aplicación tópica de W16P576 en un modelo de pioderma canina. ANIMALES: Nueve perros Beagle de laboratorio. MÉTODOS Y MATERIALES: en un estudio cruzado ciego para el evaluador con un período de aclarado de ocho semanas, los perros fueron tratados tópicamente dos veces al día con W16P576 WECMEP o su vehículo, comenzando tres días antes de la exposición bacteriana. El día de la exposición, cada perro fue tratado con dos concentraciones de una cepa clínica de S. pseudintermedius en lados opuestos del cuerpo. El tratamiento tópico se continuó durante 11 días y las lesiones de pioderma se evaluaron y puntuaron durante 14 días. RESULTADOS: todos los perros desarrollaron lesiones consistentes con pioderma bacteriana. Las puntuaciones de las lesiones fueron generalmente más altas en el lado inoculado con una mayor concentración de bacterias. El tratamiento con W16P576 redujo significativamente el desarrollo de la lesión y aceleró la resolución de las lesiones, en comparación con el placebo. CONCLUSIÓN: la aplicación tópica de W16P576 redujo notablemente el desarrollo de lesiones en este estudio de prueba de actividad. Se requieren estudios clínicos para estimar los beneficios en perros con pioderma natural en condiciones de campo.